Clinical Scorecard: FDA clears pTau217 blood test for Alzheimer's disease

At a Glance

Key Highlights

• FDA cleared Elecsys pTau217 Plasma blood test for Alzheimer's disease
• Test aids in identifying amyloid pathology
• Returns classifications: positive, intermediate, or negative
• Highly concordant with amyloid PET imaging
• Designed for use on Roche cobas laboratory instruments

Guideline-Based Recommendations

Diagnosis

• Use test results alongside clinical information and other findings

Management

• Consider further testing (e.g., PET imaging, CSF testing) based on results

Monitoring & Follow-up

• Not established for predicting future dementia or tracking therapeutic responses

Risks

• Test results should not be used in isolation for diagnosis

Patient & Prescribing Data

Patients aged 55 years and older with cognitive decline

May help identify patients for further evaluation

Clinical Best Practices

• Incorporate test into existing laboratory workflows
• Use in conjunction with other diagnostic evaluations

Related Resources & Content

• Roche Press Release